JP2021505634A - 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断 - Google Patents

膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断 Download PDF

Info

Publication number
JP2021505634A
JP2021505634A JP2020531722A JP2020531722A JP2021505634A JP 2021505634 A JP2021505634 A JP 2021505634A JP 2020531722 A JP2020531722 A JP 2020531722A JP 2020531722 A JP2020531722 A JP 2020531722A JP 2021505634 A JP2021505634 A JP 2021505634A
Authority
JP
Japan
Prior art keywords
cdkn2a
patients
measuring
expression level
bladder cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020531722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505634A5 (https=
Inventor
コリン ピー． ディニー，
コリン ピー． ディニー，
Original Assignee
トライゼル リミテッド
トライゼル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トライゼル リミテッド, トライゼル リミテッド filed Critical トライゼル リミテッド
Publication of JP2021505634A publication Critical patent/JP2021505634A/ja
Publication of JP2021505634A5 publication Critical patent/JP2021505634A5/ja
Priority to JP2023163165A priority Critical patent/JP2023165858A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
JP2020531722A 2017-12-12 2018-12-11 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断 Pending JP2021505634A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023163165A JP2023165858A (ja) 2017-12-12 2023-09-26 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762597473P 2017-12-12 2017-12-12
US62/597,473 2017-12-12
PCT/US2018/064829 WO2019118389A1 (en) 2017-12-12 2018-12-11 Cdkn2a companion diagnostic for bladder cancer interferon therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023163165A Division JP2023165858A (ja) 2017-12-12 2023-09-26 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断
JP2026025751A Division JP2026069683A (ja) 2017-12-12 2026-02-19 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断

Publications (2)

Publication Number Publication Date
JP2021505634A true JP2021505634A (ja) 2021-02-18
JP2021505634A5 JP2021505634A5 (https=) 2022-01-11

Family

ID=66820952

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020531722A Pending JP2021505634A (ja) 2017-12-12 2018-12-11 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断
JP2023163165A Pending JP2023165858A (ja) 2017-12-12 2023-09-26 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023163165A Pending JP2023165858A (ja) 2017-12-12 2023-09-26 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断

Country Status (4)

Country Link
US (2) US20200360499A1 (https=)
EP (1) EP3723780A4 (https=)
JP (2) JP2021505634A (https=)
WO (1) WO2019118389A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118389A1 (en) 2017-12-12 2019-06-20 Trizell Limited Cdkn2a companion diagnostic for bladder cancer interferon therapy
TW202203962A (zh) * 2020-03-30 2022-02-01 英商崔澤爾有限公司 用於治療癌症之組合物及方法
WO2024014580A1 (ko) * 2022-07-13 2024-01-18 이왕재바이오연구소 주식회사 엑소좀에서 발현되는 바이오 마커를 이용하는 인공지능 기반 암 진단용 정보제공 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130059303A1 (en) * 2011-09-06 2013-03-07 Francois Radvanyi Cdkn2a as a prognostic marker in bladder cancer
EP2819694B1 (en) * 2012-03-02 2019-11-20 Board Of Regents, The University Of Texas System The use of a panel of urinary cytokines to predict response to bcg therapy for bladder cancer
US20150252412A1 (en) * 2012-08-31 2015-09-10 Massachusetts Institute Of Technology High-definition dna in situ hybridization (hd-fish) compositions and methods
WO2019118389A1 (en) 2017-12-12 2019-06-20 Trizell Limited Cdkn2a companion diagnostic for bladder cancer interferon therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RASPOLLINI, M.R. ET AL., HUM PATHOL, vol. 57, JPN6022041974, 2016, pages 78 - 84, ISSN: 0005210683 *
SHORE, N.D. ET AL., J CLIN ONCOL, vol. 35, no. 30, JPN6022041976, 20 October 2017 (2017-10-20), pages 3410 - 3416, ISSN: 0005210682 *

Also Published As

Publication number Publication date
US20230310566A1 (en) 2023-10-05
EP3723780A1 (en) 2020-10-21
EP3723780A4 (en) 2021-08-25
JP2023165858A (ja) 2023-11-17
WO2019118389A1 (en) 2019-06-20
US12178865B2 (en) 2024-12-31
US20200360499A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
Marks et al. Defective acute inflammation in Crohn's disease: a clinical investigation
US20110189670A1 (en) Circulating Tumor and Tumor Stem Cell Detection Using Genomic Specific Probes
Khoufache et al. Macrophage migration inhibitory factor antagonist blocks the development of endometriosis in vivo
US12178865B2 (en) CDKN2A companion diagnostic for bladder cancer interferon therapy
EP2944961A1 (en) Markers for cancer prognosis and therapy and methods of use
KR20190057305A (ko) 자궁내막증에 대한 바이오마커로서의 microRNAs
JP2009523410A (ja) 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
EA020795B1 (ru) Генетические маркеры, ассоциированные с ответом на интерферон-альфа
Sun et al. MiR-1-3p and MiR-124-3p synergistically damage the intestinal barrier in the ageing colon
US20160032399A1 (en) Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
TW200902724A (en) Gene expression in peripheral blood mononuclear cells from children with diabetes
US10260105B2 (en) MiR-320e and colorectal cancer
JP2020500551A (ja) 検出方法
US20180057888A1 (en) Kub5/hera as a determinant of sensitivity to dna damage
JP2017534281A (ja) 潰瘍性大腸炎に特異的な診断および予後予測のバイオマーカーとしてのｍｉｒ−２１４ならびに潰瘍性大腸炎治療のためのｍｉｒ−２１４阻害剤
US20080318241A1 (en) Methods and Systems for Detecting Antiangiogenesis
US20170342503A1 (en) Xrn2 as a determinant of sensitivity to dna damage
US20120237931A1 (en) Identification and monitoring of circulating cancer stem cells
JP2011109929A (ja) 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
CN112430663B (zh) 一种用于膀胱癌诊治的生物标志物及其应用
JP2026069683A (ja) 膀胱がんインターフェロン療法のためのＣＤＫＮ２ａコンパニオン診断
US8623601B2 (en) Methods of diagnosing cancer
González-Gualda et al. A tumour-promoting senescent secretome triggered by platinum chemotherapy exploits a targetable TGFβR1/Akt-mTOR axis in lung cancer
CN105506169A (zh) 子宫肌瘤诊治标志物
CN115103918A (zh) 自闭症谱系障碍的检测和治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231011

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231109

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260219